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Abstract: The enantiomers of [18F]fluspidine, recently developed for imaging of σ1 receptors,
possess distinct pharmacokinetics facilitating their use in different clinical settings. To support
their translational potential, we estimated the human radiation dose of (S)-(−)-[18F]fluspidine and
(R)-(+)-[18F]fluspidine from ex vivo biodistribution and PET/MRI data in mice after extrapolation to
the human scale. In addition, we validated the preclinical results by performing a first-in-human
PET/CT study using (S)-(−)-[18F]fluspidine. Based on the respective time-activity curves, we
calculated using OLINDA the particular organ doses (ODs) and effective doses (EDs). The ED values
of (S)-(−)-[18F]fluspidine and (R)-(+)-[18F]fluspidine differed significantly with image-derived values
obtained in mice with 12.9 µSv/MBq and 14.0 µSv/MBq (p < 0.025), respectively. A comparable ratio
was estimated from the biodistribution data. In the human study, the ED of (S)-(−)-[18F]fluspidine
was calculated as 21.0 µSv/MBq. Altogether, the ED values for both [18F]fluspidine enantiomers
determined from the preclinical studies are comparable with other 18F-labeled PET imaging agents.
In addition, the first-in-human study confirmed that the radiation risk of (S)-(−)-[18F]fluspidine
imaging is within acceptable limits. However, as already shown for other PET tracers, the actual ED
of (S)-(−)-[18F]fluspidine in humans was underestimated by preclinical imaging which needs to be
considered in other first-in-human studies.
Keywords: image based internal dosimetry; [18F]fluspidine; preclinical hybrid PET/MRI; radiation
safety; σ1 receptors
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1. Introduction
The existence of various tissues of the sigma opioid receptor (σ) was postulated first by
Martin et al. in 1976 [1]; nowadays it has been proven to be a non-opioid receptor (Sigma Non-Opioid
Intracellular Receptor 1; σ1 receptor). This receptor plays an important role in the cellular functions
associated with the endocrine, immune, and nervous systems; however, the physiological function
of the σ1 receptor is not yet fully understood [2]. Furthermore, this protein interacts with a
variety of psychotomimetic drugs, including cocaine and amphetamines. Various diseases like
neuropsychiatric and vascular diseases as well as cancer seem to be related to dysfunctions of
the σ1 receptor [3–5]. Therefore, studying this protein with positron emission tomography (PET)
could contribute to a better understanding and further evaluation of the pathophysiological role
of σ1 receptors in diseases [6]. For imaging of σ1 receptors several radioligands were developed
and used in human such as [18F]FPS [7] and [18F]FM-SA4503 [6]. The latter study showed that
the σ1 receptor density is decreased in different brain structures in patients with early Alzheimer’s
and Parkinson’s disease. Recently, our group developed and tested the chiral σ1 receptor ligand
[18F]fluspidine in preclinical studies in mice and piglets [8], which revealed high brain uptake
of the two enantiomers (R)-(+)-[18F]fluspidine and (S)-(−)-[18F]fluspidine along with marked
enantioselectivity with regard to their biokinetics. As a consequence, the binding potential (BPnd)
of (R)-(+)-[18F]fluspidine is 5- to 10-fold higher in comparison to (S)-(−)-[18F]fluspidine in σ1-rich
areas of the porcine brain [9], most probably due to differences in their affinity towards σ1 receptors
((R)-(+)-[18F]fluspidine: Ki = 0.57 nM; (S)-(−)-[18F]fluspidine: Ki = 2.3 nM; [10]). These preclinical
data indicated a suitability of both enantiomers of [18F]fluspidine for different clinical issues. For the
first-in-human investigation of σ1 receptors in brain we have chosen (S)-(−)-[18F]fluspidine as the
enantiomer with the faster pharmacokinetics for reasons of feasibility in clinical routine (German
clinical trial register ID: DRKS00008321).
A radiation dose assessment, i.e., calculations of the absorbed and effective doses per unit activity
administered is mandatory for the translation of novel radiotracers from preclinical to clinical study
phases. These calculations are mainly based on biokinetic models using data obtained in biodistribution
or imaging studies in animals. Usually rodents [11–15] or monkeys [16–19] are used and require the
application of computational phantoms [20–23]. With rodents, both the organ harvesting method and
the dynamic hybrid imaging method are feasible to collect biokinetic data which is later extrapolated to
human anatomy (concerning organ mass and time scaling) [20]. By the organ harvesting method, the
tissue activity concentration is quantified by gamma-counting and converted into percent of injected
activity accumulated per organ (%ID) after dissection of the animals at different points post injection
of a radiotracer. With the imaging method, the biokinetics of the radiotracer is investigated using
clinical or small-animal PET/CT or PET/MRI systems. The activity in the organs as well as the weight
is extracted after delineation with the help of the anatomical CT or MR images, and the organ-specific
%ID values are calculated. Eventually, interspecies extrapolation of the respective animal data has
to be performed to calculate the human effective dose. However, the standard procedure of these
established models may lead to underestimation of radiation risk in humans as we could recently show
with (−)-[18F]flubatine [24] and (+)-[18F]flubatine [25]. The preclinical dosimetry in mice revealed an
underestimation of the effective dose in humans of up to 50% which could be improved only slightly
when using piglets as larger species (underestimation ~38%).
In this work, we report on the dosimetry and biodistribution of both enantiomers of the σ1
receptor ligand [18F]fluspidine based on in vivo and ex vivo data from mice which we obtained by the
dynamic hybrid PET/MR imaging method as well as by an organ harvesting study. Subsequently, we
report on the first-in-human internal dosimetry using (S)-(−)-[18F]fluspidine obtained in four healthy
volunteers. This direct comparison of preclinical with clinical data is assumed to advance the use
of small animal PET/MRI for the assessment of the radiation risk of novel PET imaging agents in
humans. The preclinical dosimetry reveals the ED for (S)-(−)-[18F]fluspidine and (R)-(+)-[18F]fluspidine
comparable with other 18F-labeled PET imaging agents, despite significant differences of the EDs due
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to enantiomer specific tracer kinetics. The ED estimate from the first-in-human study confirmed that
the radiation risk of (S)-(−)-[18F]fluspidine imaging is within accepted limits. However, as shown in
previous studies, the ED in humans is underestimated by up to 50% by using preclinical imaging for
internal dosimetry. This fact needs to be considered when applying for first-in-human studies based
on preclinical biokinetic data scaled to human anatomy.
2. Results
In this study, we have investigated the preclinical dosimetry of both enantiomers of the σ1
receptor ligand [18F]fluspidine based on in vivo and ex vivo data from CD-1 mice after i.v. injection.
The biokinetic data was obtained either by dynamic hybrid small animal PET/MR imaging or by an
organ harvesting approach in mice followed by extrapolation to the human scale. Subsequently,
the ODs were estimated with OLINDA and the ED calculated using tissue weighting factors
published by ICRP 60 [26] and ICRP 103 [27]. Finally, we performed a first-in-human dosimetry
study of (S)-(−)-[18F]fluspidine in four healthy volunteers confirming the radiation safety of that
promising radioligand.
2.1. Human Dosimetry Estimation from Small Animal PET/MRI and Biodistribution Studies
Representative dynamic PET images in mice obtained at different times p.i. of (S)-(−)-[18F]fluspidine
and (R)-(+)-[18F]fluspidine are shown in Figure 1. A high initial uptake of activity in liver, small
intestines, and gallbladder wall as well as a fast clearance during the investigation time was observed.
Exemplary time-activity curves (TACs) with fitting functions to calculate the numbers of disintegration
(please see Section 4.4) for (S)-(−)-[18F]fluspidine and (R)-(+)-[18F]fluspidine are presented in Figure S1.
The corresponding mean uptake values (in terms of % ID at a particular time p.i.; Tables S3 and S4)
reflect lower values of the S-enantiomer in comparison to the R-enantiomer.
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Figure 1. Representative time series (MIP) of mice (a), (b), and a volunteer (c) after i.v. injection of 
(S)-(−)-[18F]fluspidine (a), (c) and (R)-(+)-[18F]fluspidine (b). Furthermore, the diagram shows the scan 
protocol for humans clarifying the dynamic and static PET part as well as the urine voiding intervals. 
Figure 1. Representative time series (MIP) of mice (a), (b), and a volunteer (c) after i.v. injection of
(S)-(−)-[18F]fluspidine (a), (c) and (R)-(+)-[18F]fluspidine (b). Furthermore, the diagram shows the scan
protocol for humans clarifying the dynamic and static PET part as well as the urine voiding intervals.
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The biodistribution study confirmed the enantiomer-specific performance (Figure S2).
The decrease of the %ID values of (S)-(−)-[18F]fluspidine during the course of the study (Table S1) is
contrasted by a stagnation of the washout of activity after administration of (R)-(+)-[18F]fluspidine
(Table S2), which is most obvious in brain, spleen, kidneys, and lung. Accordingly, animal PET
and biodistribution data revealed higher ODs and EDs for (R)-(+)-[18F]fluspidine compared to
(S)-(−)-[18F]fluspidine (Tables 1 and 2). We estimated the highest OD values for (S)-(−)-[18F]fluspidine
and (R)-(+)-[18F]fluspidine from animal PET/MRI in urinary bladder, kidneys, spleen, gallbladder
wall, and liver (Table 1). From animal organ harvesting derived biodistribution, the highest values
were estimated in kidneys, upper large intestine, small intestine, and lungs (Table 2).
For (S)-(−)-[18F]fluspidine we estimated the ED in humans from animal PET/MRI and organ
harvesting derived biodistribution to be 12.9 ± 0.4 µSv/MBq and 14.0 ± 0.5 µSv/MBq, respectively,
and for (R)-(+)-[18F]fluspidine to be 16.7 µSv/MBq and 18.4 µSv/MBq, respectively Accordingly,
for (R)-(+)-[18F]fluspidine the ED is higher than for (S)-(−)-[18F]fluspidine in both experimental
conditions; however, statistical significance could be calculated only for the imaging-derived data
(p = 0.025, students t test, n = 3/group). For the organ harvesting study, a t test is not applicable due to
methodical reasons.
Detailed biokinetic data expressed as mean %ID of the mice organ harvesting or imaging method
can be found in the supplemental material (Tables S1–S4).
Table 1. OD and ED in µSv/MBq based on the imaging method with a small animal PET/MRI. ODs
calculated for the adult male model (73.7 kg, implemented in OLINDA) based on mouse biodistribution
and organ geometry data that were scaled proportionately to human circumstances.
Target Organ
(S)-(−)-[18F]Fluspidine (R)-(+)-[18F]Fluspidine
OD SD ED Contr. SD OD SD ED Contr. SD
Adrenals 10.50 0.74 0.09 0.01 11.00 1.55 0.09 0.01
Brain 10.10 2.34 0.10 0.02 13.20 1.19 0.13 0.01
Breasts 5.93 0.10 0.71 0.01 6.19 1.77 0.74 0.21
Gallbladder Wall 25.60 9.57 0.22 0.08 30.10 11.90 0.26 0.10
LLI Wall 14.00 1.48 0.84 0.09 13.80 1.39 0.83 0.08
Small Intestine 23.10 3.22 0.20 0.03 22.60 1.92 0.20 0.02
Stomach Wall 10.50 0.60 1.26 0.07 12.70 1.10 1.52 0.13
ULI Wall 20.50 4.96 1.23 0.30 25.60 2.19 1.54 0.13
Heart Wall 9.85 0.60 0.08 0.01 10.50 1.31 0.09 0.01
Kidneys 37.60 14.80 0.32 0.13 26.90 2.74 0.23 0.02
Liver 25.00 3.23 1.00 0.13 26.10 4.65 1.04 0.19
Lungs 10.40 2.30 1.25 0.28 10.80 0.89 1.30 0.11
Muscle 7.57 0.07 0.07 0.00 7.86 1.96 0.07 0.02
Ovaries 11.50 0.82 0.92 0.07 11.90 1.95 0.95 0.16
Pancreas 10.90 0.69 0.09 0.01 24.80 1.79 0.21 0.02
Red Marrow 10.80 0.37 1.30 0.04 12.80 1.27 1.53 0.15
Osteogenic Cells 12.70 0.13 0.13 0.00 14.00 3.18 0.14 0.03
Skin 5.61 0.02 0.06 0.00 5.82 1.73 0.06 0.02
Spleen 26.10 7.29 0.22 0.06 31.80 20.00 0.27 0.17
Testes 7.46 0.39 0.00 0.00 7.63 2.04 0.00 0.00
Thymus 7.19 0.11 0.06 0.00 7.52 2.21 0.06 0.02
Thyroid 7.61 1.09 0.30 0.04 10.10 0.35 0.41 0.01
Urinary Bladder Wall 58.00 15.90 2.32 0.64 55.70 19.30 2.23 0.77
Uterus 12.80 1.28 0.11 0.01 13.00 1.49 0.11 0.01
Total Body 8.68 0.14 0.00 0.00 9.13 1.67 0.00 0.00
ED 12.9 0.4 14.0 0.5
ED ICRP 60 14.8 1.7 15.2 1.9
OD = organ dose; ED contr. = effective dose contribution; SD = standard deviation, mean over 3 animals;
LLI = large lower intestine; ULI = upper large intestine.
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Table 2. OD and ED in µSv/MBq based on mouse organ harvesting after dissection and organ counting
in a gamma-counter. The organ geometry data were scaled proportionately to human circumstances.
ODs calculated for the adult male model (73.7 kg, implemented in OLINDA).
Target Organ
(S)-(−)-[18F]Fluspidine (R)-(+)-[18F]Fluspidine
OD ED Contr. OD ED Contr.
Adrenals 36.0 0.3 18.6 0.2
Brain 12.4 0.1 12.6 0.1
Breasts 11.2 1.3 11.3 1.4
Gallbladder Wall 15.5 0.1 14.0 0.1
LLI Wall 19.0 1.1 16.4 1.0
Small Intestine 31.9 0.3 25.1 0.2
Stomach Wall 14.8 1.8 14.3 1.7
ULI Wall 33.3 2.0 25.6 1.5
Heart Wall 17.9 0.2 22.3 0.2
Kidneys 35.6 0.3 27.6 0.2
Liver 12.5 0.5 10.3 0.4
Lungs 30.5 3.7 45.5 5.5
Muscle 7.2 0.1 7.1 0.1
Ovaries 17.0 1.4 24.9 2.0
Pancreas 26.2 0.2 21.7 0.2
Red Marrow 13.6 1.6 13.5 1.6
Osteogenic Cells 19.6 0.2 19.1 0.2
Skin 9.1 0.1 8.7 0.1
Spleen 17.6 0.2 17.2 0.1
Testes 11.2 - 10.8 -
Thymus 12.0 0.1 19.3 0.2
Thyroid 11.7 0.5 11.5 0.5
Urinary Bladder Wall 13.9 0.6 20.2 0.8
Uterus 15.9 0.1 14.9 0.1
Total Body 12.5 - 12.2 -
ED 16.7 18.4
ED ICRP 60 17.3 20.1
OD = organ dose; ED contr. = effective dose contribution; LLI = large lower intestine; ULI = upper large intestine.
2.2. Human Dosimetry from the First-in-Human Study
There were no adverse effects reported in any of the four volunteers after i.v. injection of
(S)-(−)-[18F]fluspidine, and no significant changes in vital signs were monitored.
Typical TACs and fitted curves are shown in Figure S3. The results of the dose assessment are
presented in Table 3. Detailed biokinetic data expressed as mean %ID of the clinical study can be found
in the supplemental material (Table S5).
The highest OD values for (S)-(−)-[18F]fluspidine were estimated in gallbladder wall, small
intestine, stomach, and kidneys. The effective dose of (S)-(−)-[18F]fluspidine for humans was estimated
to be 21.0 ± 1.3 µSv/MBq. A summary of the ED estimates for both enantiomers of [18F]fluspidine,
the different methods and species can be found in Table 4.
The toxicity results (please see supplemental methods and results) of the pathologic examination
in Wistar rats indicated that (S)-(−)-fluspidine after single intravenous administration did not cause
toxicological changes in pathological and histopathological parameters on day 2 and day 15. The no
observed effect level (NOEL) of (S)-(−)-fluspidine after single intravenous administration in this study
for both day 2 and day 15 was determined to be 620 µg/kg (highest tested dose).
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Table 3. First-in-human data, OD and ED in µSv/MBq. The ODs were calculated for the adult male
model (73.7 kg, implemented in OLINDA) based on human biodistribution and organ geometry data.
Target Organ
(S)-(−)-[18F]Fluspidine
OD SD ED Contr. SD
Adrenals 15.3 1.1 0.1 0.0
Brain 22.6 4.2 0.2 0.1
Breasts 6.5 0.5 0.8 0.1
Gallbladder Wall 60.7 10.6 0.5 0.1
LLI Wall 16.6 5.1 1.0 0.3
Small Intestine 56.9 10.6 0.5 0.1
Stomach Wall 31.5 3.3 3.8 0.4
ULI Wall 24.3 5.2 1.5 0.3
Heart Wall 17.7 1.3 0.2 0.0
Kidneys 31.1 5.2 0.3 0.0
Liver 76.0 17.7 3.0 0.4
Lungs 28.2 2.9 3.4 0.3
Muscle 7.8 0.5 0.1 0.0
Ovaries 13.8 1.0 1.0 0.5
Pancreas 15.9 0.7 0.1 0.0
Red Marrow 23.2 2.2 2.8 0.1
Osteogenic Cells 18.0 1.6 0.2 0.0
Skin 5.3 0.5 0.1 0.0
Spleen 24.0 4.2 0.2 0.0
Testes 8.0 2.6 0.8 0.4
Thymus 7.5 0.7 0.1 0.0
Thyroid 8.4 1.4 0.3 0.1
Urinary Bladder Wall 24.7 3.4 1.0 0.1
Uterus 13.0 0.7 0.1 0.1
Total Body 11.4 0.3 0.0 0.0
ED 21.0 1.3
ED ICRP 60 22.1 0.8
OD = organ dose; ED contr. = effective dose contribution; SD = standard deviation, mean over four volunteers;
LLI = large lower intestine; ULI = upper large intestine.
Table 4. Comparison of dosimetry results (ED) for different PET tracers including the current study
with [18F]fluspidine.
Tracer Target Organ Clinical (µSv/MBq) Preclinical (µSv/MBq) Reference
(S)-(−)-[18F]fluspidine brain, tumor 21.0 12.9 (mouse, imaging)16.7 (mouse, harvesting) this study
(R)-(+)-[18F]fluspidine brain, tumor n.a. 14.0 (mouse, imaging)18.4 (mouse, harvesting) this study
(−)-[18F]flubatine
(formerly [18F]NCFHEB)
brain 23.4 12.5 (mouse)14.7 (piglet, imaging) [24]
(+)-[18F]flubatine brain 23.0
12.1 (mouse, imaging)
14.3 (piglets, imaging) [25]
[18F]FEDAA1106 brain 36
21.0 (male mouse)
26.0 (female mouse) [28]
[18F]FET brain tumor 16.5 9.0 [29,30]
2-[18F]F-A85380 brain 19.4 n.a. [31]
[18F]FDG multiple 19.0 n.a. [32]
3. Discussion
With this study, we support the clinical translation of the novel radiotracer [18F]fluspidine for
imaging of σ1 receptors by preclinical and clinical radiation dosimetry studies. We have derived
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internal radiation dosimetry of the enantiomers (S)-(−)-[18F]fluspidine and (R)-(+)-[18F]fluspidine by
organ harvesting and dynamic small animal PET/MR imaging in mice and compared the results of
both methods with each other. Finally, we performed a clinical study to calculate radiation doses for
humans following intravenous injection of (S)-(−)-[18F]fluspidine and to validate the results achieved
by the animal dose assessment. The main findings are (i) methodical issues regarding radiation
estimates for humans extrapolated from small animals; (ii) radiation dose differences between the two
enantiomers (S)-(−)-[18F]fluspidine and (R)-(+)-[18F]fluspidine; and (iii) confirmation of the radiation
safety of (S)-(−)-[18F]fluspidine for clinical studies.
We would like to point out that both the preclinical as well as the clinical studies have shown
that the novel σ1 receptor imaging agent (S)-(−)-[18F]fluspidine fulfils the requirements regarding
radiation dose in human clinical trials, although in comparison to the extrapolated animal data a
1.6-fold higher value (p < 0.001, students t test, n = 3/group) of the actual ED has been calculated from
the human study.
The main reasons for this discrepancy are assumed to be related to several methodological
shortcomings of the extrapolation procedures. One deficiency is the assumption in the adult male
model implemented in OLINDA 1.0, that the anatomical organ arrangement between mice and
humans is identical. However, a simple mass extrapolation in animals and using a human phantom
that does not take into account the spatial interactions of the organs in comparison to mouse (reflected
by the S-values), is insufficient. A novel approach using the implementation of rodent specific
dosimetry models in OLINDA 2.0 [33] remains to be assessed. Another limitation belongs to the
extrapolation methods used to adapt the animal time scale and uptake scale. The currently most
qualified methods [34] cancel out at least partially species differences in metabolism as well as body
and organ weight. However, a compensation for species-specific differences in the tracer uptake, i.e.,
differences in the expression of the target in the respective organ, is not possible. Furthermore, the
aspect of the effect of significant size differences between the species on dose estimations has been
recently addressed by our group during the clinical translation of a radioligand for imaging of nicotinic
acetylcholine receptors by directly comparing dosimetry in piglets (~15 kg) and humans [24,25].
However, an underestimation of the radiation dose in humans of about 40% remained. Hence, a
simple size-dependent effect is not likely, as reflected by the findings of Zanotti-Fregonara et al. [16].
In this study, both under- and overestimations of the effective dose in humans, ranging from −11% to
+72%, by using biokinetic data for nine PET tracers obtained in monkeys are reported (baboons and
rhesus monkeys, weight: 9.9 ± 3.6 kg). Altogether, these findings clearly indicate the need to take
species-specific pharmacokinetics into account of both the radiotracer and radiometabolites as they
potentially result in significant deviations in the dosimetry of the radiotracer under investigation.
The direct comparison between the two preclinical methods of dose estimation via organ
harvesting and dynamic small animal PET imaging reveals negligible differences regarding ED values
of the respective [18F]fluspidine enantiomer under investigation. However, for both radiotracers,
slightly lower organ doses were detected in the imaging than in the organ harvesting approach. This
outcome is most likely related to anesthesia-mediated effects on hemodynamics and metabolism [35,36],
although based on the currently available data no mechanistic explanation can be provided.
The attractive approach reported by Bretin et al. [14] to compensate for deviations between these two
preclinical methods by correcting the image derived TACs according to the activity values measured
ex vivo by gamma-counting after scanning is not applicable here, because in contrast to our study they
used anesthetized animals for the organ harvesting method as well.
Another interesting finding in our preclinical study is that although both enantiomers accumulate
specifically in σ1 receptor rich regions in the brain [9], they exhibit pronounced differences in their
ED values. This is most probably related to marked differences in their pharmacokinetics and
pharmacology [9]. The TACs of (S)-(−)-[18F]fluspidine and (R)-(+)-[18F]fluspidine in mice, obtained
by either organ harvesting or PET imaging, are different in terms of maximal uptake value (in %ID)
and the shape of the curve. Hence, slower elimination rates, up to 1.3-fold higher OD values and
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subsequently higher ED values (p = 0.025, students t test; PET imaging approach with n = 3/group)
were observed for the (R)-(+)-enantiomer. Following an initial washout, detected for both enantiomers,
the elimination of activity stagnates in nearly all organs after administration of (R)-(+)-[18F]fluspidine.
This corresponds to the enantioselective tracer kinetics already observed in most regions of the
pig brain and the significantly higher BPnd values of (R)-(+)-[18F]fluspidine [9]. Assuming such
enantioselective pharmacokinetics for other tissues as well due to the expression of σ1 receptors in
almost all tissues [3,37], the slower washout of (R)-(+)-[18F]fluspidine from the organ tissues was to be
expected. Statistical significance in terms of ED was attained solely with the imaging-derived data
because only with this approach a complete set of biokinetic data of one animal and hence individual
OD and ED values are available. By contrast, no individual time-activity data can be obtained from
ex vivo biodistribution studies because each animal contributes to only a single OD value.
The strong correlation between pharmacokinetics and ED values is demonstrated also by
a comparison of the herein investigated enantiomers of [18F]fluspidine with the enantiomers of
[18F]flubatine, a ligand for α4β2 nicotinic acetylcholine receptors [24,25]. Our preclinical and clinical
dosimetry studies of (+)-[18F]flubatine and (−)-[18F]flubatine, both possessing very similar biokinetics
in different species up to humans, revealed no significant differences in the ED between the two
enantiomers. No significant differences were observed also regarding the ED values of the enantiomers
of [11C]mirtazapine, although the enantioselectivity of the OD values estimated for brain corresponds
with the enantioselectivity of the brain kinetics [38]. Altogether, findings on either different or
comparable ED values of enantiomers of chiral compounds used as PET imaging agents strongly
reflect the influence of enantioselective processes during their interaction with the chiral compounds
in biological systems such as receptor proteins or metabolizing enzymes [39].
Although the ED values of both enantiomers of [18F]fluspidine show a 1.6 fold difference,
the excretion route of 18F is similar. A renal/hepatobiliary clearance can be assumed from the two
preclinical models due to a high uptake of activity in the intestinal and hepatobiliary as well as renal
tract, which results in comparatively high OD values in the liver, gallbladder wall, small intestine,
kidneys, and urinary bladder. Furthermore, in fully awake animals used in the organ harvesting
distribution study the urinary bladder is less exposed to radiation than in anesthetized mice due to
urinary retention under isoflurane narcosis [40–43].
Based on the preclinical biokinetic data shown herein as well as in our recent PET study
using piglets [9], different clinical applications came into consideration for the two enantiomers
of [18F]fluspidine. The relatively slow kinetics and nearly constant activity accumulation
of (R)-(+)-[18F]fluspidine in the observed organs and tissues which might translate into high
signal-to-noise ratios in σ1 expressing tumors and metastases makes this enantiomer interesting for
cancer imaging. By contrast, the (S)-(−)-enantiomer provided favorable properties for neuroimaging
and data analysis with a special regard to kinetic modeling due to the high initial brain uptake
and fast washout and was therefore selected for a first-in-human study. The radiation dose of
(S)-(−)-[18F]fluspidine in human tissues has been estimated after injection of the radiotracer in two
female and two male healthy volunteers. The hereby obtained TACs (presented in Figure S3) confirmed
the assumed renal/hepatobiliary clearance. The radioligand was rapidly removed from brain, stomach,
liver, and spleen within one hour post injection, while a slower clearance from red marrow, already
observed in earlier σ1 receptor ligand studies [44,45], reflects the high expression of σ1 receptors
in rapidly dividing tissues. Hence, it was proposed that σ1 receptor ligands may also be used as
proliferation markers [46]. The effective dose of the σ1 receptor ligand (S)-(−)-[18F]fluspidine is
21.0 µSv/MBq, well within the range of other 18F-labeled diagnostic radiotracers (Table 4). Thus,
in combination with a NOEL of at least ~600 µg/kg, the application of (S)-(−)-[18F]fluspidine as PET
imaging agent in humans is safe.
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4. Materials and Methods
The time-dependent radioactive data for the animal and human studies was acquired with
three different techniques. (i) The mice were scanned in a preclinical small animal PET/MRI while
the (ii) human study was performed on a clinical PET/CT system. In addition the (iii) ex vivo
biodistribution study in mice was performed by post mortem organ dissection followed by counting
for radioactivity in a gamma counter.
4.1. Synthesis of [18F]Fluspidine
The synthesis of (S)-(−)-[18F]fluspidine for the human application was performed as described by
Fischer et al. [8] with minor modifications. Briefly, the tracer was produced by phase transfer catalyst
assisted nucleophilic substitution (100 ◦C, 15 min) using a precursor molecule with a tosyl-leaving
group (2 mg in 1 mL dry CH3CN). Purification and formulation was achieved by semipreparative
HPLC and solid phase extraction, respectively. Overall synthesis time was 50 min, radiochemical purity
exceeded 97% and specific activity was determined to be 230 ± 160 GBq/µmol (n = 16 syntheses).
For the animal studies, enantiomerically pure (S)-(−)-[18F]fluspidine and (R)-(+)-[18F]fluspidine
was prepared on a TRACERlab FX F-N synthesizer (GE Healthcare) as described in previous
publications [9,47]. The radiochemical purity of (R)-(+) or (S)-(−)-[18F]fluspidine was >99%, and
the specific activity at the end of the synthesis was 650 and 870 GBq/µmol, respectively [48].
4.2. Preclinical Dosimetry Studies
All animal experiments were approved by the responsible institutional and federal state
authorities (Landesdirektion Leipzig; TVV 08/13). A toxicological study was confirmed and can
be found in the supplemental material.
4.2.1. Ex Vivo Biodistribution Study (Organ Harvesting Method)
Female CD-1 mice (age: 12 weeks) received an intravenous injection of (R)-(+)-[18F]fluspidine
(0.35 ± 0.08 MBq; weight: 29.8 ± 2.2 g; n = 28) or (S)-(−)-[18F]fluspidine (0.39 ± 0.05 MBq; weight:
29.3 ± 1.9 g; n = 22). Two to three animals per time point were sacrificed by cervical dislocation at 5,
15, 30, 45, 60, 90, 120, 180, and 240 min. p.i. The brain, heart, lung, stomach, small intestine (SI), large
intestine (LI), liver, kidneys, urinary bladder (UB), spleen, thymus, pancreas, adrenals, and ovaries
were dissected, weighed, and the accumulated activity quantified in a gamma-counter (WIZARD
Automatic Gamma Counter, PerkinElmer, Waltham, MA, USA) to determine the percentage injected
activity (dose) per gram of tissue (%ID/g).
In addition, the sampling time p.i. and %ID/g values were scaled proportionately to human
magnitude (please see Equations (1) and (2) in Section 4.4) prior to dose estimation with OLINDA/EXM
(Vanderbilt University, Nashville, TN, USA, version 1.0).
4.2.2. In Vivo Imaging Based Study (Imaging Method)
The animals were initially anesthetized with 4% of isoflurane and were positioned prone in a
small-animal PET/MRI system (nanoScan® PET/MRI, MEDISO, Budapest, Hungary) equipped with
respiratory monitoring, heated mouse bed (37 ◦C), and inhalation anesthesia (1.8% isoflurane in a
60% oxygen/40% air gas mixture at 250 mL/min airflow; Anaesthesia Unit U-410, agntho’s, Lidingö,
Sweden; Gas blender 100 series, MCQ Instruments, Rome, Italy). Prior to the PET scan, a scout image
MR sequence was done to outline the animal dimensions. Female CD-1 mice (age: 12 weeks, weight:
30.9 ± 1.3 g) were injected via the tail vein with (S)-(−)-[18F]fluspidine (13.2 ± 3.0 MBq; n = 3) or
(R)-(+)-[18F]fluspidine (12.6 ± 1.4 MBq; n = 3) in a volume of 200 µL saline. The injected dose was
calculated by the difference of the radioactivity in the syringe before and after the injection. A dynamic
whole body animal PET scan of 105 min length (Figure 1) was started simultaneously. This scanning
time was chosen to represent the protocol of the human study (after time extrapolation according to
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Equation (2)) based on a priori biokinetic information from the ex vivo investigation. Following the PET
scan, a 20 min T1-weighted whole body MR scan (gradient echo sequence, TR = 20 ms; TE = 3.2 ms)
was performed for anatomical orientation after co-registration and attenuation correction at the
reconstruction step.
4.3. First-in-Human Dosimetry Study (Imaging Method)
The first-in-human use of (S)-(−)-[18F]fluspidine was authorized by the competent authorities
in Germany, the Federal Institute for Drugs and Medical Devices (Bundesamt für Arzneimittel
und Medizinprodukte, BfArM) and the Federal Office for Radiation Protection (Bundesamt für
Strahlenschutz, BfS) as well as by the local ethics committee and was conducted in accordance with
the Declaration of Helsinki. Informed consent was obtained from four healthy volunteers (2 f, 2 m;
age: 23 ± 3 years; weight: 56 ± 4 kg). The volunteers were positioned supine with the arms down in
a clinical PET/CT system (Biograph 16, Siemens, Erlangen, Germany) and received an intravenous
injection of 255 ± 9 MBq (S)-(−)-[18F]fluspidine. Simultaneously, the PET scan was started. It was
divided into a dynamic part up to 2 h p.i. (7 frames) and a static part up to 7 h p.i. (3 frames) with
increasing time per bed position (from 1.5 up to 6 min) as shown in Figure 1. The volunteers left the
investigation table four times to stretch out. All urine was collected, weighed, and the activity was
determined in a gamma-counter (Packard Cobra II 5003 Auto Gamma Counting System, GMI, Ramsey,
MN, USA) cross calibrated to the PET/CT system.
4.4. Image Reconstruction and Analysis of the Preclinical and Clinical Data
The PET images were iteratively (ordered-subsets expectation maximization, OSEM) reconstructed
(preclinical: 4 iterations, 6 subsets; clinical: 4 iterations, 8 subsets) and corrected for decay, randoms,
scatter, and dead time, µ-maps for attenuation correction of PET-emission data were derived from
the CT or MR [49] structural data, respectively. The PET data were re-binned into 10 time frames
(preclinical: 4 × 5 min, 1 × 10 min, and 5 × 15 min; clinical: 4 × 12 min, 3 × 16 min, 1 × 32 min,
1 × 40 min, and 1 × 48 min), and the reconstructed PET/MRI and PET/CT images were co-registered
manually with ROVER (ABX, advanced chemical compounds, Radeberg, Germany, version 2.1.17).
Quantitative evaluation was performed by drawing volumes of interest (VOI) for brain, gallbladder,
large intestine, small intestine, stomach, heart, kidneys, liver, lungs, pancreas, red marrow (backbone,
pelvis, sternum), spleen, thyroid, testes, and urinary bladder (Figure S4). The PET derived biokinetic
data is expressed as percentage of injected activity (dose) per cubic centimeter (%ID/cm3).
For human dosimetry estimation from animal biodistribution and PET/MR imaging, animal
organ masses and time scale was extrapolated to human magnitudes [20,30]. At first, the organ-specific










with the fraction of the injected activity in the corresponding human organ = %IDorganhuman , the fraction of
injected activity per gram animal organ tissue = %IDgmouse and morganhuman the mass of the corresponding
human organ [50]. At second, a time scale extrapolation is needed due to differences in the metabolic







including the human time scale = thuman, the animal time scale = tmouse and the ratio of animal and
human body weights = mmousemhuman . The allometric coefficient of 0.25 generally describes the differences
between the two species regarding physiological processes such as biological half-life [20,50,51].
Hence, using this time extrapolation approach with an exponent of 1/4, a 105 min PET scan in mice is
sufficient to represent 10 h in humans (Figure S1).
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The human dosimetry estimation was performed with the data extrapolated as well as the
genuine human data using OLINDA/EXM software [33]. The time-activity curves were estimated
by exponential fitting and calculating the time integral, which equals the number of disintegrations
(NODs) per organ during the observation period normalized to 1 Becquerel administered activity
dose. Due to narcosis, mice did not void urine during the imaging session. Therefore, activity data
of the urinary bladder was derived from the image for each time point. In contrast, for humans the
activity concentration data of the urinary bladder was obtained in a more direct approach. At first, the
activity and volume of urine was determined in the last frame of the PET scan before each micturition.
Afterwards, the voided urine was collected, weighed, and the activity of three aliquots (assuming
1 mL = 1 g) determined with a gamma counter, and the activity of the whole sample estimated.
The difference between imaged and sampled urine activity is equal to the residue of radioactive
urine in the urinary bladder. To calculate the NOD in the human urinary bladder, the time-activity







(%IDi + %IDi+1) (ti+1 − ti) (3)
with the fraction of injected activity %IDi at the time ti and the cumulated activity of the urinary
bladder i.e., the NOD % I˜DUB.
Furthermore, the NODs of the gastric system were calculated following the ICRP GI model
(ICRP 30) as implemented in OLINDA 1.0. The NODs obtained either from the EXM module or the
trapezoidal equation were transferred to OLINDA. The OD for the chosen hermaphroditic adult male
phantom is estimated following the MIRD scheme [52]. The S values [53,54] are pre-calculated and
implemented for the respective phantom in OLINDA. Subsequently, the ED contribution from each
organ is calculated by multiplying the ODs with the respective tissue weighting factors as published
by the International Commission on Radiological Protection (ICRP 103 [27]) for each organ. As these
weighting factors require the ICRP 110 phantom [55] which is not available in OLINDA version 1.0, the
ED results by using the tissue weighting factors published by ICRP 60 [26] were estimated in addition
(Tables 1–3).
5. Conclusions
The results achieved from this study support the potential of (S)-(−)-[18F]fluspidine as a clinically
applicable PET imaging agent for the investigation of σ1 receptors. As shown before, the extrapolation
of preclinical data obtained by dosimetry studies in small animals by either organ harvesting or
PET imaging results in an underestimation of the human ED values most due to limitations in
allometric scaling and species-specific target expression. However, the imaging approach excels in
comparison to the organ harvesting method for obtaining extensive whole body kinetic information
using a significantly reduced number of animals. Thus, small animal image based dosimetry is
recommended as the preferable method for preclinical dose estimates prior to the application for
first-in-human studies. However, preclinical dose estimates remain preliminary and need to be
confirmed in human studies.
While we are presently evaluating the utility of (S)-(−)-[18F]fluspidine for quantification of
pathological changes in the expression of σ1 receptors in major depressive disorder, the entire potential
of the enantioselective pharmacokinetics of (S)-(−)-[18F]fluspidine and (R)-(+)-[18F]fluspidine for
imaging of σ1 receptors in neuropsychiatric, neuro-oncological, and oncological diseases remains to be
further investigated.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/21/
9/1164/s1.
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